Douglas K. Graham

Molecular genetic analysis of a small bowel primitive neuroectodermal tumor.

Disseminated nasopharyngeal natural killer cell lymphoblastic lymphoma in a child.

Successful treatment of severe aplastic anemia in children using standardized immunosuppressive therapy with antithymocyte globulin and cyclosporine A.

Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia.

A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation.

Precursor natural killer cell leukemia.

Natural killer cell neoplasms.

BAC to the future? comparative genomic hybridization and genotyping pediatric leukemia cytogenetic abnormalities.

TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.

Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children.

Mer tyrosine kinase (MerTK) promotes macrophage survival following exposure to oxidative stress.

Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.

Thymoma in children: report of 2 cases and review of the literature.

Gray zone lymphomas in pediatric patients.

Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.

Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.

Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.

Constitutive induction of pro-inflammatory and chemotactic cytokines in cystathionine beta-synthase deficient homocystinuria.

TAM receptors in leukemia: expression, signaling, and therapeutic implications.

Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus.

Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia.

Moderate aplastic anemia in children: preliminary outcomes for treatment versus observation from a single-institutional experience.

Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

Dual ALK and MYC rearrangements leading to an aggressive variant of anaplastic large cell lymphoma.

UNC1062, a new and potent Mer inhibitor.

Molecular Pathways: MERTK Signaling in Cancer.

Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia.

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.

UNC569, a novel small molecule Mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.